These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11534306)

  • 1. A case for lipid lowering? Response to Dr Paul Durrington.
    Yudkin JS
    Diabet Med; 2001 May; Suppl 3():11-2. PubMed ID: 11534306
    [No Abstract]   [Full Text] [Related]  

  • 2. A case for lipid-lowering?
    Durrington P
    Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: Lipid-lowering drugs after myocardial infarction.
    Lancet; 1975 Mar; 1(7905):501-2. PubMed ID: 46964
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipids and diabetes mellitus: a review of therapeutic options.
    Goguen JM; Leiter LA
    Curr Med Res Opin; 2002; 18 Suppl 1():s58-74. PubMed ID: 12365820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering drug therapies: the evidence.
    Packard C
    Proc Nutr Soc; 2000 Aug; 59(3):423-4. PubMed ID: 10997662
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence-based medicine and the selection of lipid-lowering therapy in type 2 diabetes.
    Aguilar-Salinas CA; Mehta R; Gomez-Diaz RA
    Curr Diab Rep; 2012 Jun; 12(3):221-3. PubMed ID: 22451238
    [No Abstract]   [Full Text] [Related]  

  • 7. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk.
    Duntas L; Kolovou G
    Future Cardiol; 2011 Mar; 7(2):137-44. PubMed ID: 21453018
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of lipid-lowering medication in patients with acute myocardial infarction (Worcester Heart Attack Study).
    Goldberg RJ; Ockene IS; Yarzebski J; Savageau J; Gore JM
    Am J Cardiol; 1997 Apr; 79(8):1095-7. PubMed ID: 9114770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid disorders in NIDDM: implications for treatment.
    Taskinen MR; Smith U
    J Intern Med; 1998 Nov; 244(5):361-70. PubMed ID: 9845851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipids: diagnosis and therapy in type 2 diabetes].
    Wascher TC; Paulweber B; Toplak H; Saely C; Drexel H
    Wien Klin Wochenschr; 2012 Dec; 124 Suppl 2():28-30. PubMed ID: 23250461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies.
    Orloff DG; Blazing MA; O'Connor CM
    Am Heart J; 1999 Nov; 138(5 Pt 1):S406-12. PubMed ID: 10539805
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of lipids and type 2 diabetes.
    Hermayer KL
    Curr Cardiol Rep; 2004 Nov; 6(6):443-50. PubMed ID: 15485606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of the UKPDS Study for general practice care of type 2 diabetes.
    Brankin E; Fisher M
    Br J Gen Pract; 1999 Dec; 49(449):1009. PubMed ID: 10824353
    [No Abstract]   [Full Text] [Related]  

  • 14. [HDL cholesterol as protective factor. Deficiency threatens the diabetic heart].
    MMW Fortschr Med; 2003 Nov; 145(48):60. PubMed ID: 14725005
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
    Wägner AM; Ordóñez-Llanos J; Jorba O; Pérez A
    Metabolism; 2004 Nov; 53(11):1516. PubMed ID: 15558848
    [No Abstract]   [Full Text] [Related]  

  • 16. Currently available lipid-lowering agents.
    Levy RI
    Hosp Pract (Off Ed); 1988 Jun; 23 Suppl 1():14-21. PubMed ID: 3134381
    [No Abstract]   [Full Text] [Related]  

  • 17. Simvastatin, fenofibrate, and rhabdomyolysis.
    Jacob SS; Jacob S; Williams C; Deeg MA
    Diabetes Care; 2005 May; 28(5):1258. PubMed ID: 15855605
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
    Burgess DC; Hunt D; Li L; Zannino D; Williamson E; Davis TM; Laakso M; Kesäniemi YA; Zhang J; Sy RW; Lehto S; Mann S; Keech AC
    Eur Heart J; 2010 Jan; 31(1):92-9. PubMed ID: 19797259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating lipid abnormalities in patients with type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2001 Dec; 88(12A):37N-40N. PubMed ID: 11788129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing prescription of drugs for secondary prevention of myocardial infarction. Lipid lowering drugs should be considered too.
    Taylor A; Reckless JP
    BMJ; 1996 Jan; 312(7025):252. PubMed ID: 8563613
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.